Skip to main content
Download PDF

A diagnostic model based on 18F-FDG PET/CT parameters in improving the differential diagnosis of invasive thymic epithelial tumors and anterior mediastinal lymphomas

BMC Medical Imaging volume 24, Article number: 14 (2024) Cite this article

Abstract

Background

Accurately distinguishing between invasive thymic epithelial tumors (TETs) and anterior mediastinal lymphoma before surgery is crucial for subsequent treatment choices. But currently, the diagnosis of invasive TET is sometimes difficult to distinguish from anterior mediastinal lymphoma.

Objective

To assess the application of fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computer tomography (PET/CT) in the differential diagnosis of TETs and anterior mediastinal lymphomas.

Methods

18F-FDG PET/CT images of 133 invasive TETs and anterior mediastinal lymphomas patients were retrospectively analyzed. In particular, the tumor’s longest diameter and maximum standardized uptake value (SUVmax) were evaluated. The SUVmax and longest diameter values of the two groups were analyzed by using the receiver operating characteristic (ROC) curve to determine the optimal threshold and diagnostic efficiency.

Results

Age, myasthenia gravis, SUVmax and tumor longest diameter differed significantly between invasive TETs and anterior mediastinal lymphomas patients. The tumor location, calcification, relationship with adjacent vessels and distant metastasis differed significantly between the groups. The ROC analysis showed an AUC for SUVmax and tumor longest diameter of 0.841 and 0.737. Respectively, the cutoff values with the best diagnostic performance were 9.65 (sensitivity: 77.78%, specificity: 81.97%) and 6.65 (sensitivity: 80.56%, specificity: 62.30%) for SUVmax and tumor longest diameter. The diagnostic model of SUVmax, calcification, relationship with surrounding blood vessels, lymph node metastasis and lung metastasis in the highest AUC of 0.935 (sensitivity: 90.16%, specificity: 88.89%). In addition, we incorporated splenic involvement and metastatic sub-diaphragmatic lymph node into Model 2 as a new predictive model 3 for differential diagnosis and found a significant improvement in the diagnostic performance of Model 3.

Conclusion

The diagnostic model composed of 18F-FDG PET parameters is improving the differential diagnosis of invasive TETs and anterior mediastinal lymphomas.

Peer Review reports

Introduction

Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas and thymic neuroendocrine tumors are the most common malignancies in the anterior mediastinum in adults [1]. The 2004 version of the World Health Organization (WHO) classification subdivides TETs into A, AB, B1, B2, B3 and C (thymic carcinomas) [2]. Of note, most types A and AB thymomas have low malignant potential, types B1, B2 and B3 are more aggressive, and type C is a highly aggressive tumor [3]. Types A and B thymomas are usually at stage I-II while most type B2/B3/C thymomas are at stage III-IV [4]. On the other hand, Thymic lymphomas is one of the most common malignant lymphomas originating in the anterior mediastinal region, which is hard to differentially diagnosis with TETs [5]. Practically, optimal therapeutic options are different for TETs and anterior mediastinal lymphomas. Surgery is the mainstay treatment for TETs, while radiotherapy and chemotherapy are more preferred for anterior mediastinal lymphomas [6, 7]. Thus, making an accurate differential diagnosis between TETs and anterior mediastinal lymphomas is very critical to avert thoracotomy for anterior mediastinal lymphomas patients [8, 9].

Currently, magnetic resonance (MR) and computed tomography (CT) are widely used to evaluate anterior mediastinal masses, but there are still some deficiencies in distinguishing histological subtypes [10, 11]. Different from invasive TETs and anterior mediastinal lymphomas, most of noninvasive TETs can be provided definitive diagnosis by using MR or CT scan [12]. Clinically, there is considerable overlap between invasive TETs and anterior mediastinal lymphomas in imaging features [13], differential diagnosis remains a puzzle.

Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/CT (PET/CT) is now mainly used for diagnosis, staging, detection of recurrence and response evaluation of many malignant tumors [14, 15]. Several studies have confirmed the value of 18F-FDG PET/CT in the differentiation of benign and malignant anterior mediastinal masses [16, 17]. Furthermore, some studies also have found that 18F-FDG PET/CT has excellent application value in the differentiating thymoma and anterior mediastinal lymphomas [18, 19]. Most studies have focused on differentiating thymoma and anterior mediastinal lymphomas while ignoring the different degree of malignancy among thymoma subtypes. In fact, the diagnosis of invasive TETs is sometimes difficult to distinguish from anterior mediastinal lymphomas [20]. To our knowledge, there have been relatively few studies on the comparisons between invasive TETs and anterior mediastinal lymphomas. Therefore, we expect that 18F-FDG PET/CT image features combines with clinical information can play a critical role in differentiating invasive TETs and anterior mediastinal lymphomas.

In this study, we retrospectively investigated the differences of invasive TETs and anterior mediastinal lymphomas and to assess whether 18F-FDG PET/CT image features combines with clinical information can distinguish invasive TETs and anterior mediastinal lymphomas. Furthermore, we constructed the diagnostic model composed of 18F-FDG PET parameters and evaluated the diagnosis efficiency of this model.

Patients and methods

Ethical approval

The study conforms to the ethical guidelines in accordance with the Helsinki Declaration as revised in 2013 and was approved by Fujian Provincial Hospital review board and ethical committee.

Patients

Between January 2013 and January 2018, a total of 205 patients with thymic tumors including invasive TETs and anterior mediastinal lymphoma were retrospectively recruited. All patients were required to meet all the following inclusion criteria: (1) The diagnosis of invasive TETs or anterior mediastinal lymphoma were confirmed by surgical pathology or needle biopsy; (2) 18F-FDG PET/CT was performed before treatment; (3) clinical information of patients was complete. Finally, 133 patients were included in the analysis (Fig. 1). The clinical information of all patients was summarized in Table 1.

Fig. 1
figure 1

Patient inclusion flowchart

Full size image
Table 1 Clinical and 18F-FDG PET/CT image parameter comparisons between invasion thymoma and anterior mediatinal lymphoma patients
Full size table

Image acquisition protocol

All patients fasted for at least 6 hours before 18F-FDG administration. Patients with a blood glucose level higher than 180 mg/dL (10.0 mmol/L) or lower than 72 mg/dL (4.0 mmol/L) were rescheduled. Patients were implanted with indwelling intravenous three-way pipes, followed by 18F-FDG manual administration with 5.5 MBq (0.15 mCi) per body weight. PET/CT studies were acquired from mid-thigh to the base of the skull [21] using a total-body PET/CT scanner (Discovery LS, GE Healthcare, Milwaukee, WI.) after 50 \(\sim\) 60 min resting in dark room. CT scans (tube current 120 mAs, voltage 140 kV, rotation time 0.5 s, pitch 1.35, and slice thickness 5 mm.) of the torso were obtained which reconstructed in a 512 \(\times\) 512 matrix. The thoracic CT images were reconstructed by using a standard kernel. Emission data were acquired with 4 min/bed position in 2-dimensional mode; and PET images were reconstructed using ordered subset expectation maximization (OSEM).

Image analysis

All images evaluation has been performed in a functional imaging workstation (GE, Xeleris version 3.0) and reviewed in standard planes. Two nuclear physicians with 10 years of FDG PET/CT diagnostic experience and fellowship trained in thoracic imaging independently analyzed the PET/CT images blinded to the clinical data. Discordance was resolved by consensus. Semiquantitative parameter maximal standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) was measured semiautomatically over the volume of interests (VOIs) of metabolically active lesions. Thoracic CT images were reviewed by two board-certified radiologists with more than 10 years of experience blinded to the PET images. CT images indicators include tumor location, edge, adjacency and distant metastasis.

Statistical analysis

All statistical analysis was conducted using SPSS (version 20.0; IBM, Armonk, New York, USA). Unpaired Student’s t test and Chi-square test (or Fisher’s exact tests) were used to examine differences between the groups. The differences in age, SUVmax and tumor longest diameter values between TETs and anterior mediastinal lymphoma were analyzed using Student’s t test, while that Chi-square test was used for the position, boundary, calcification, relationship with surrounding blood vessels and distant metastasis. Single factor analysis screened out statistically significant analysis indicators (P < 0.05) and conducted multivariate binary logistic regression analysis to determine the analysis indicators with independent risk factors (P < 0.05) and construct a model. The subject operating characteristic curve (ROC) was plotted for the model and independent risk factors. The optimal diagnostic efficacy parameters [sensitivity (Sen), specificity (Spe), area under curve (AUC), and 95% confidence interval] were determined using the maximum Youden index. Diagnostic model was conducted based on multivariate logistic regression analysis. A ROC curve analysis was used to examine SUVmax and tumor longest diameter using medcalc software (version 20.0.3). All comparisons were two-sided and P value less than 0.05 was considered as statistical significance. All values in the text and tables were given as the mean ± SD (standard deviation).

Results

Clinical characteristics

In this study, a total of 133 patients were included in the analysis, including 61 invasive TETs and 72 thymic lymphomas patients. As shown in Table 1, our data was indicated that myasthenia gravis (66.7%, 38 of 61 patients vs. 0%, 0 of 72 patients, P < 0.001) and age (55.84 ± 11.43 vs. 28.97 ± 10.37, P < 0.05) were significantly different between the invasive TETs and anterior mediastinal lymphoma patients. And there was no difference between the two groups with respect to gender (%male-54.1% vs. 55.6%; P \(=\) 0.866). Also, pathological type of malignancies in the anterior mediastinum was shown in Table 2. Thymic Carcinoma was the most common subtype in the thymic epithelial tumors, and diffuse large B-cell lymphoma is the most in the anterior mediastinal lymphomas.

Table 2 Pathological type of malignancies in the anterior mediastinum
Full size table

Comparison of 18F-FDG PET/CT imaging features between invasive TETs and anterior mediastinal lymphomas

Comparisons of imaging features between invasive TETs and anterior mediastinal lymphomas were shown in Table 1. There were significant differences between invasive TETs and anterior mediastinal lymphomas groups in calcification (29.5%, 18 of 61 patients vs. 0%, 0 of 72 patients, P < 0.001), distant metastasis (55.7%, 34 of 61 patients vs. 36.1%, 26 of 72 patients, P \(=\) 0.023), encased vessels (14.8%, 9 of 61 patients vs. 34.7%, 25 of 72 patients, P \(=\) 0.009), while no differences in blurred tumor borders (73.8%, 45 of 61 patients vs. 75.0%, 54 of 72 patients, P \(=\) 0.871). Furthermore, the mean (±SD) values for tumor largest diameter in invasive TETs and anterior mediastinal lymphomas were 6.72± 2.99 and 7.99 ±1.83 cm. The tumor largest diameter for invasive TETs was significantly higher than that in anterior mediastinal lymphomas (P \(=\) 0.003). The mean (±SD) values for SUVmax in invasive TETs and anterior mediastinal lymphomas were 7.63± 4.58 and 15.68± 8.18 cm. The SUVmax for invasive TETs was significantly lower than that in anterior mediastinal lymphomas (P < 0.001). Representative images of invasive TETs and anterior mediastinal lymphomas were shown in Figs. 2 and 3.

Fig. 2
figure 2

PET/CT findings of a 62-year-old patient with type B3 thymoma. A Right anterior medial malleolus soft tissue mass shadow, adjacent blood vessels were not clear and calcified calcification inside the tumor was observed (arrow). B A high metabolism signal (arrow) was seen in the tumor, SUVmax \(=\) 3.9. C A small amount of fluid in the right thoracic cavity (arrow). D Right pleural hypermetabolism nodules (arrow), SUVmax \(=\) 2.5

Full size image
Fig. 3
figure 3

PET/CT findings of a 23-year-old patient with diffuse large B-cell lymphoma. A A large soft tissue mass in the anterior medial malleolus which was composed of multiple nodules. Tumor invaded into the front chest wall and partial adjacent large blood vessels (arrow). B Significant radioactive abnormal signals (arrow) in the tumor, SUVmax \(=\) 35.5. C Tumor edge was lobulated with a fissure-like necrotic region inside the tumor (arrow). D Radioactive defect inside necrotic region (arrow)

Full size image

The differentiating efficacy of SUVmax, tumor largest diameter and diagnosis models in invasive TETs and anterior mediastinal lymphomas

As shown in Fig. 4 and Table 3, ROC curve analysis was used to evaluate the differential efficacy of SUVmax and tumor largest diameter. ROC analysis showed an AUC for SUVmax and tumor largest diameter of 0.841 and 0.737. Respectively, the cutoff values with the best diagnostic performance were 9.65 (sensitivity: 77.78%, specificity: 81.97%) and 6.65 (sensitivity: 80.56%, specificity: 62.30%) for SUVmax and tumor largest diameter. Then, two different diagnostic models including model 1: SUVmax plus tumor largest diameter, model 2: SUVmax, calcification, relationship with surrounding blood vessels, metastasis (lymph node and lung) were constructed by logistic regression analysis. The results showed that the model 2 with SUVmax, calcification, relationship with surrounding blood vessels, metastasis (lymph node and lung) resulted in a highest AUC of 0.935 (sensitivity: 90.16%, specificity: 88.89%) (Fig. 4 and Table 3). The AUC of diagnostic model 2 was better than tumor largest diameter, SUVmax, and model 1 with SUVmax and tumor largest diameter (all P < 0.05). In addition, we incorporated splenic involvement and metastatic sub-diaphragmatic lymph node into Model 2 as a new predictive model 3 for differential diagnosis and found a significant improvement in the diagnostic performance of Model 3 (Fig. 4 and Table 3).

Table 3 Differential diagnostic efficiency of 18F-FDG PET/CT parameters and different diagnosis models between invasive TETs and anterior mediastinal lymphomas
Full size table
Fig. 4
figure 4

The ROC curves of tumor largest diameter, SUVmax, model 1, model 2 and model 3. ROC analysis to determinate the sensitivity and specificity of the tumor largest diameter, SUVmax, model 1, model 2 and model 3 for differentiating invasive TETs from anterior mediastinal lymphoma

Full size image

Discussion

Thymic tumors and lymphomas, while rare, are the most frequent tumors of the anterior mediastinal compartment in adults [22]. Most of non-invasive TETs present as sharply demarcated round or oval soft tissue masses in anterior mediastinal on CT, which usually can be accurately diagnosed [23]. On the contrary, imaging features of CT between invasive TETs and anterior mediastinal lymphoma frequently overlap and sometimes are difficult to differentiate, including lobulated, off-midline and mass effect [23, 24]. Although 18F-FDG PET/CT already has been a common clinical diagnostic tool for anterior mediastinal tumors and useful for differentiating benign from malignant tumors, the differential diagnosis between invasive TETs and anterior mediastinal lymphoma is still not well resolved. Importantly, treatment guidelines of invasive TETs and anterior mediastinal lymphomas are distinct. Surgical resection is the mainstay of treatment in invasive TETs, while chemotherapy is more preferred for lymphoma [6, 16, 25]. Accurate diagnosis of invasive TETs and anterior mediastinal lymphomas is critical in planning treatment strategies. However, most studies have focused on the differential diagnosis of thymoma and anterior mediastinal lymphomas while ignoring the different degree of malignancy among thymoma subtypes. In our study, we are primarily focused on comparing the disease characteristics between invasive TETs and anterior mediastinal lymphomas by using 18F-FDG PET/CT combined with clinical information.

Mediastinal lymphomas is predominantly occurred in young adult life [25]. Previous studies reported that there was a certain value for the age in differentiating TETs and anterior mediastinal lymphomas [18, 26]. In this current study, the mean age of patients with invasive TETs was significantly higher than that of anterior mediastinal lymphomas patients (55.84 ± 11.43 years vs 28.97 ± 10.37 years, P < 0.001). Therefore, the present study supports the previous finding that age is associated with the differential diagnosis of invasive TETs and anterior mediastinal lymphomas. Additionally, myasthenia gravis is an important paraneoplastic manifestation of TETs patients, but may also present in patients with anterior mediastinal lymphomas [27]. Notably, our study reveals that 52.5% (38/61) invasive TETs patients with myasthenia gravis while none of the 72 patients with anterior mediastinal lymphomas had myasthenia gravis. Overall, we demonstrated the differences in age and myasthenia gravis between invasive TETs and anterior mediastinal lymphomas patients.

18F-FDG PET/CT metabolic parameters SUVmax is independent variables to predict malignancy [28]. Recent research suggests that there are certain clinical value for SUVmax in differentiating benign and malignant TETs [29]. Giorgio Treglia et al demonstrated that the mean SUVmax in thymic carcinomas was significantly higher than low-risk thymomas [30]. Moreover, SUVmax also can be used in differentiating TETs and anterior mediastinal lymphomas [18, 31]. Catherine T Byrd et al reported that anterior mediastinal tumors with SUVmax less than 7.50 were likely thymoma while anterior mediastinal lymphomas were likely with SUVmax greater than 12.85, and as for tumors with SUVmax between 7.50 and 12.85, it was still need to be biopsied to rule out lymphoma [19]. In fact, most of the anterior mediastinal lymphomas were with high SUVmax value, while invasive TETs with high-grade malignancy are usually with high SUVmax value. Here, our results reveal that the mean SUVmax of patients with anterior mediastinal lymphomas was significantly higher than that of invasive TETs patients (7.63 ± 4.58 vs 15.68 ± 8.18, P < 0.001). Meanwhile, we found that the mean maximal diameter of patients with invasive TETs was shorter than that of anterior mediastinal lymphomas patients. (6.72 ± 2.99 cm vs 7.99 ± 1.83 cm, P <0.001). ROC analysis found that SUVmax (AUC \(=\) 0.840) and tumor largest diameter (AUC \(=\) 0.737), suggesting that SUVmax could play an important role in the differentiation of invasive TETs and anterior mediastinal lymphomas. Furthermore, the diagnostic model 2 (SUVmax plus calcification plus relationship with surrounding blood vessels plus lymph node metastasis plus lung metastasis) could significantly improve the diagnostic ability compared to tumor largest diameter, SUVmax and model 1 (SUVmax plus tumor largest diameter).

The presence of lesions in the subdiaphragmatic nodes and spleen is important for distinguishing between different conditions in clinical practice. However, in our analysis, we found that there was no statistically significant association between lesions in the subdiaphragmatic nodes and spleen. Unfortunately, 19.5% of patients in our study had metastatic subdiaphragmatic lymph nodes and 8.3% had infiltration of the spleen. However, when we evaluated the diagnostic performance of these parameters alone, we found that they were not very accurate, with AUC values of 0.574 and 0.646 respectively. Therefore, we incorporated these parameters into a new predictive model (Model 3) for differential diagnosis and found that it significantly improved the diagnostic performance compared to the previous models.

The utilization of diagnostic models can enhance the accuracy of disease diagnosis and aid clinicians in making treatment decisions. By relying on a few key parameters, clinicians can accurately diagnose diseases without solely relying on image interpretation. This can potentially save time and resources, leading to more efficient and effective patient care. This study had some shortcomings that should be acknowledged. Our study was a retrospective cohort study, and the results need to be confirmed in a prospective study. In addition, although this study included many cases, all data were from single-center.

Conclusion

In conclusion, the diagnostic model composed of 18F-FDG PET parameters is improving the differential diagnosis of invasive TETs and anterior mediastinal lymphomas. We also reveal the differences in age and myasthenia gravis between invasive TETs and anterior mediastinal lymphomas patients. 18F-FDG PET/CT combined with clinical information present an important diagnostic modality for differential diagnosis of invasive TETs and anterior mediastinal lymphomas, and in turn to provide accurate therapeutic strategies for mediastinal malignancies.

Availability of data and materials

All relevant data are within the article.

References

  1. Detterbeck FC. Evaluation and treatment of stage I and II thymoma. J Thorac Oncol. 2010;5(10):S318–22.

    Article  Google Scholar 

  2. Marx A, Strobel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014;9(5):596–611.

    Article  CAS  PubMed  Google Scholar 

  3. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thor Surg. 2004;77(4):1183–8.

    Article  Google Scholar 

  4. Ruffini E, Filosso PL, Oliaro A. The role of surgery in recurrent thymic tumors. Thor Surg Clin. 2009;19(1):121–31.

    Article  Google Scholar 

  5. Ackman JB, Verzosa S, Kovach AE, et al. High rate of unnecessary thymectomy and its cause. Can computed tomography distinguish thymoma, lymphoma, thymic hyperplasia, and thymic cysts? Eur J Radiol. 2015;84(3):524–33.

    Article  PubMed  Google Scholar 

  6. Savage KJ. Primary mediastinal large B-cell lymphoma. Blood. 2022;140(9):955–70.

    Article  CAS  Google Scholar 

  7. Shepherd A, Riely G, Detterbeck F, et al. Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. J Thorac Oncol. 2017;12(4):745–51.

    Article  Google Scholar 

  8. Liu TZ, Zhang DS, Liang Y, et al. Treatment strategies and prognostic factors of patients with primary germ cell tumors in the mediastinum. J Cancer Res Clin Oncol. 2011;137(11):1607–12.

    Article  CAS  PubMed Central  Google Scholar 

  9. Kang CH, Kim YT, Jheon S, et al. Surgical treatment of malignant mediastinal nonseminomatous germ cell tumor. Ann Thorac Surg. 2008;85(2):379–84.

    Article  Google Scholar 

  10. Li HR, Gao J, Jin C, et al. Comparison between CT and MRI in the Diagnostic Accuracy of Thymic Masses. J Cancer. 2019;10(14):3208–13.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sadohara J, Fujimoto K, Muller NL, et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol. 2006;60(1):70–9.

    Article  PubMed  Google Scholar 

  12. Tomiyama N, Muller NL, Ellis SJ, et al. Invasive and noninvasive thymoma: distinctive CT features. J Comput Assist Tomogr. 2001;25(3):388–93.

    Article  CAS  PubMed  Google Scholar 

  13. Xie Y, Zhang S, Liu J, et al. Value of CT spectral imaging in the differential diagnosis of thymoma and mediastinal lymphoma. Br J Radiol. 2019;92(1095):20180598.

    Article  PubMed  Google Scholar 

  14. Groheux D. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. Semin Nucl Med. 2022;52(5):508–19.

    Article  PubMed  Google Scholar 

  15. Ayati N, Sadeghi R, Kiamanesh Z, et al. The value of (18)F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(2):428–48.

    Article  CAS  PubMed  Google Scholar 

  16. Watanabe T, Shimomura H, Mutoh T, et al. Positron emission tomography/computed tomography as a clinical diagnostic tool for anterior mediastinal tumors. Surg Today. 2019;49(2):143–9.

    Article  CAS  PubMed  Google Scholar 

  17. Luzzi L, Campione A, Gorla A, et al. Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg. 2009;36(3):475–9.

    Article  PubMed  Google Scholar 

  18. Wang G, Du L, Lu X, et al. Multiparameter diagnostic model based on (18)F-FDG PET and clinical characteristics can differentiate thymic epithelial tumors from thymic lymphomas. BMC Cancer. 2022;22(1):895.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Byrd CT, Trope WL, Bhandari P, et al. Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma. J Thorac Cardiovasc Surg. 2023;165(1):371-381 e371.

    Article  PubMed  Google Scholar 

  20. Liu H, Chen Y. Mediastinal T-lymphoblastic lymphoma mimicking invasive thymoma on (18)F-FDG PET/CT in a young patient. J Nucl Cardiol. 2020;27(3):1059–62.

    Article  PubMed  Google Scholar 

  21. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.

    Article  CAS  PubMed  Google Scholar 

  22. Azizad S, Sannananja B, Restrepo CS. Solid Tumors of the Mediastinum in Adults. Semin Ultrasound CT MRI. 2016;37(3):196–211.

    Article  Google Scholar 

  23. Strange CD, Ahuja J, Shroff GS, et al. Imaging Evaluation of Thymoma and Thymic Carcinoma. Front Oncol. 2021;11:810419.

    Article  PubMed  Google Scholar 

  24. Matsumoto T, Shimabukuro M, Okita I, et al. CT findings of malignant lymphoma of the anterior mediastinum-differentiation from invasive thymoma. Nihon Igaku Hoshasen Gakkai Zasshi. 1989;49(4):414–22.

    CAS  PubMed  Google Scholar 

  25. Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood. 2018;132(8):782–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Carter BW, Marom EM, Detterbeck FC. Approaching the patient with an anterior mediastinal mass: a guide for clinicians. J Thorac Oncol. 2014;9(9 Suppl 2):S102–9.

    Article  PubMed  Google Scholar 

  27. You S, Sun JS, Park KJ, Koh YW. Amyloid deposition in thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in a patient with myasthenia gravis: A case report. Thorac Cancer. 2020;11(3):781–4.

    Article  PubMed  PubMed Central  Google Scholar 

  28. van Gomez Lopez O, Garcia Vicente AM, Honguero Martinez AF, et al. (18)F-FDG-PET/CT in the assessment of pulmonary solitary nodules: comparison of different analysis methods and risk variables in the prediction of malignancy. Transl Lung Cancer Res. 2015;4(3):228–35.

    Google Scholar 

  29. Han S, Kim YI, Oh JS, et al. Diagnostic and prognostic values of 2-[(18)F]FDG PET/CT in resectable thymic epithelial tumour. Eur Radiol. 2022;32(2):1173–83.

    Article  PubMed  Google Scholar 

  30. Treglia G, Sadeghi R, Giovanella L, et al. Is (18)F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis. Lung Cancer. 2014;86(1):5–13.

    Article  PubMed  Google Scholar 

  31. Zhu L, Li X, Wang J, et al. Value of metabolic parameters in distinguishing primary mediastinal lymphomas from thymic epithelial tumors. Cancer Biol Med. 2020;17(2):468–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Author notes

  1. Shuo Zhou and Pokwan Tsui contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou City, Fujian Province, China

    Shuo Zhou, Meifu Lin, Guobao Chen & Wenxin Chen

  2. Medical Imaging Center, First Affiliated Hospital of Jinan University, No. 613 West Huangpu Avenue, Tianhe District, Guangzhou, 510630, Guangdong, China

    Pokwan Tsui & Xiangran Cai

Authors
  1. Shuo Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pokwan Tsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meifu Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guobao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenxin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiangran Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S Z: performed conceptualization, Methodology, formal analysis, and the original draft. PK T: performed a review and editing the manuscript, visualization and data presentation. MF L, GB C and WX C as well as S Z participated in data collection and validation. WX C and XR C participated in supervising and responsibility for the research activity planning and execution. Both S Z and PK T are considered as the first author.

Corresponding authors

Correspondence to Wenxin Chen or Xiangran Cai.

Ethics declarations

Ethics approval and consent to participate

The study conforms to the ethical guidelines in accordance with the Helsinki Declaration as revised in 2013 and was approved by Fujian Provincial Hospital review board and ethical committee. Informed consent was obtained from all subjects and/or their legal guardian(s).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, S., Tsui, P., Lin, M. et al. A diagnostic model based on 18F-FDG PET/CT parameters in improving the differential diagnosis of invasive thymic epithelial tumors and anterior mediastinal lymphomas. BMC Med Imaging 24, 14 (2024). https://doi.org/10.1186/s12880-023-01185-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12880-023-01185-1

Keywords

BMC Medical Imaging

ISSN: 1471-2342

Contact us